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Abstract
Introduction: Idiopathic pulmonary fibrosis (IPF), a fatal lung disease of unknown origin, is characterized by chronic
and progressive fibrosing interstitial pneumonia which progressively impairs lung function. Oxidative stress is one of
the main pathogenic pathways in IPF. The aim of this systematic review was to describe the type of markers of
oxidative stress identified in different biological specimens and the effects of antioxidant therapies in patients with IPF.
Methods: We conducted a systematic search of publications listed in electronic databases (Pubmed, Web of Science,
Scopus and Google Scholar) from inception to October 2017. Two investigators independently reviewed all identified
articles to determine eligibility.
Results: After a substantial proportion of the initially identified articles (n = 554) was excluded because they were
duplicates, abstracts, irrelevant, or did not meet the selection criteria, we identified 30 studies. In each study, we
critically appraised the type, site (systemic vs. local, e.g. breath, sputum, expired breath condensate, epithelial lining
fluid, bronchoalveolar lavage, and lung tissue specimens), and method used for measuring the identified oxidative
stress biomarkers. Furthermore, the current knowledge on antioxidant therapies in IPF was summarized.
Conclusions: A number of markers of oxidative stress, with individual advantages and limitations, have been described
in patients with IPF. Nevertheless, trials of antioxidant treatments have been unable to demonstrate consistent benefits,
barring recent pharmacogenomics data suggesting different results in specific genotype subgroups of patients with IPF.
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Background
Idiopathic pulmonary fibrosis (IPF) is a fatal lung
disease of unknown cause that is characterized by
chronic and progressive fibrosing interstitial pneumo-
nia with worsening dyspnea and lung function [1, 2].
Though IPF is relatively rare it is the most common
and severe form of idiopathic interstitial pneumonia
(IIP) [3]. Histologically, IPF is characterized as usual
interstitial pneumonia (UIP), a form of disease with
progressive fibrosis of the lungs [4, 5].
Risk factors for IPF include cigarette smoking, envir-
onmental factors, microbial agents, and gastroesophageal
reflux [1, 2, 6]; recent studies also support the role of
gene expression and epigenetic alterations [7, 8]. Most
of these factors are also involved in other lung patholo-
gies such as lung cancer [9, 10]. IPF symptoms include
dry cough, dyspnoea, and digital clubbing [11]. Pulmon-
ary function tests identify restrictive features (reduced
total lung capacity) and abnormal gas exchange (reduced
capacity for carbon monoxide diffusion) [1]. Diagnosis
often requires a multidisciplinary approach and, in some
cases, a lung biopsy [1, 12].
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Although IPF has long been considered a chronic inflam-
matory disorder, this concept has been revisited following
the negative results of interventional studies with anti-
inflammatory therapies [13]. IPF is now widely accepted as
a consequence of multiple interacting genetic and environ-
mental risk factors, which cause repetitive local micro-
injuries to ageing alveolar epithelium [11]. This triggers
aberrant epithelial–fibroblast communication, induction of
matrix-producing myofibroblasts, remodelling of the inter-
stitium, and dysregulated repair of the injured lung [11].
There is growing evidence that oxidative stress plays a
significant role in IPF [14, 15]. Oxidative stress is defined
as an imbalance between oxidant production and anti-
oxidant defence in favour of oxidants, that leads to cellu-
lar dysfunction and tissue damage. Due to its exposure
to relatively higher oxygen tensions than other tissues,
the lung is particularly sensitive to oxidative stress. Ex-
ogenous oxidants and pollutants further increase oxidant
production and activate inflammatory cells to generate
free radicals. Cigarette smoke, asbestos fibers, drugs and
radiations, are well-known to favour fibrotic interstitial
lung reactions [14]. Furthermore, they have been shown
to trigger the production of the reactive oxygen species
(ROS) hydroxyl radical, hydrogen peroxide, and super-
oxide radical. In the human lung, several pathways can
generate ROS, including nicotinamide adenine dinucleo-
tide phosphate oxidases, myeloperoxidase, eosinophil
peroxidase, mitochondrial electron transport chain, and
xanthine oxidase [16, 17]. In addition, superoxide may
react with nitric oxide (NO) to form various reactive
nitrogen species (RNS), such as peroxynitrite. NO is
principally produced by the inducible form of nitric
oxide synthase (iNOS, NOS2) in the lung, in particular
during inflammation. Moreover, human lung cells widely
express also the constitutive forms of NOS, that further
contribute to NO production. In general, a complex
variety of oxidants are produced in response to injuries
leading to pulmonary fibrosis. These oxidants can acti-
vate several genes related to cell growth, cell death, and
fibroblast proliferation [1].
Normal pulmonary homeostasis requires an appropri-
ate balance between intracellular and extracellular oxi-
dants and antioxidants. Lung protection against oxidants
is guaranteed by protective antioxidants and antioxidant
enzymes that include (i) small-molecular-weight antioxi-
dants (e.g., glutathione, vitamins, uric acid), (ii) mucins,
(iii) metal-binding proteins (transferrin, lactoferrin,
metallothionein, etc.), (iv) intracellular and extracellu-
lar superoxide dismutases (SODs), (v) enzymes to
reduce H2O2 (several glutathione-associated enzymes
and catalase), (vi) detoxification enzyme systems (e.g.,
glutathione-S-transferases), and (vii) other redox regu-
latory thiol proteins (e.g., thioredoxin-peroxiredoxin
system and glutaredoxins) [16–19].
These majority of these enzymes, localized in bron-
chial and alveolar epithelial cells, alveolar macrophages,
and the extracellular milieu, are regulated by the nuclear
factor erythroid-derived 2-like2 protein (Nrf2), which
controls the expression of several antioxidant pulmonary
proteins. The importance of Nrf2 in IPF has been dem-
onstrated through experiments in mice in which defi-
ciency of this transcription factor significantly enhanced
bleomycin-induced pulmonary fibrosis [20]. It is likely
that the induction of antioxidant enzymes and related
proteins after exposure to insults may protect the lung
and promote damage repair. Conversely, reduced induc-
tion or inactivation of antioxidant enzymes may result in
a continuous redox imbalance, that may contribute to
the progression of pulmonary fibrosis (Fig. 1).
Given the accepted role of oxidative stress in IPF, the
aim of the present systematic review was to critically as-
sess published studies investigating the type of oxidative
stress markers in different biological specimens, the ad-
vantages and limitations of the methods used for their
measurement, and potential therapeutic implications in
this patient group.
Search strategy and study selection
A systematic search of publications listed in electronic
databases (Pubmed, Web of Science, Scopus and Google
Scholar) from inception to October 2017, was conducted
using the following terms: “oxidative stress”, “IPF”, “idio-
pathic pulmonary fibrosis” as well as combinations of
these terms. Two investigators independently reviewed
the identified articles to determine their eligibility. Studies
were considered eligible if they met the following criteria:
(1) assessment of oxidative stress (OS) biomarkers in any
type of biological specimens from IPF patients; and (2)
English language full-text publications involving humans
in peer reviewed journals. Abstracts were screened inde-
pendently and, if relevant, full articles were obtained and
reviewed. References in the retrieved articles were also
reviewed to identify additional studies. A flow chart show-
ing the study selection is presented in Fig. 2.
From a total of 513 initially identified studies, 289
were excluded after the first screening, mainly because
they were duplicates. The majority of the remaining 224
studies were also excluded, mainly because they were
either in abstract format, irrelevant, or did not met the
selection criteria. A total of 30 studies were included in
the systematic review.
Biomarkers of oxidative stress in IPF
The identification of oxidative stress biomarkers in IPF
patients was performed in different biological specimens,
primarily blood and serum (n = 10 studies), bronchoalve-
olar lavage fluid (BALF, n = 10), and lung tissue (n = 9),
with relatively few studies using sputum (n = 1), breath
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(n = 1), epithelial lining fluid (ELF) (n = 4), and expired
breath condensate (EBC) (n = 4), (Table 1).
Systemic blood biomarkers of OS in IPF
Unlike EBC, sputum or breath, the measurement of OS
biomarkers in blood has significant advantages in terms of
reproducibility and sensitivity, but also challenges regard-
ing their biological and clinical relevance when compared
to local concentrations. Rahman et al. [21] measured pa-
rameters of oxidant/antioxidant balance in the plasma of
12 patients with IPF (7 non-smokers and 5 smokers) and
31 healthy subjects (23 non-smokers and 8 smokers).
Plasma TEAC (trolox equivalent antioxidant capacity) was
significantly lower both in healthy smokers and in patients
with IPF regardless of their smoking status, when com-
pared to healthy non-smokers. By contrast, there were no
significant differences in plasma protein thiol concentra-
tions between patients with IPF and healthy subjects.
Plasma concentrations of malondialdehyde (MDA)
were higher in healthy smokers than in non-smokers,
however they were similar between IPF patients who
smoked and healthy smokers. The concentrations of
products of lipid peroxidation were higher in patients
with IPF, regardless of their smoking status, when com-
pared to healthy non-smokers. These findings indicated




Fig. 1 Oxidative stress plays a critical role in the pathogenesis of IPF through: a) promoting inflammation by increasing production of cytokines
and growth factor, which causes b) fragmentation of extracellular matrix, increased myofibroblastic differentiation, fibrogenesis and
epithelialization; c) as a consequence of DNA damage and p53 activation, ROS promote apoptosis of airway epithelial cells resulting in an
impaired ability to regenerate alveolar epithelium. These alterations contribute to the progression of pulmonary fibrosis
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accompanied by a significant imbalance in systemic
redox status.
Daniil et al. [22] evaluated plasma oxidative stress by
measuring total hydroperoxides using a spectrophotomet-
ric method named D-ROMs [23]. Serum concentrations
of hydroperoxides in IPF patients were significantly higher
than controls (356 ± 14 vs 201 ± 10 UCarr, p < 0.001). No
significant differences were observed between ex-smokers
and never smokers. In the IPF group, there was a signifi-
cant positive correlation between serum concentrations of
hydroperoxides and severity of dyspnea, according to the
Medical Research Council (MRC) chronic dyspnea score.
Moreover, there was a negative correlation between the
serum concentrations of hydroperoxides, forced vital cap-
acity (FVC), and the diffusing capacity of carbon monox-
ide (DLCO). Nevertheless, no significant correlations were
observed between oxidative stress parameters and Forced
Expiratory Volume in the 1st second (FEV1), FEV1/FVC
ratio, PaO2, and PaCO2. The authors suggested that the
measurement of hydroperoxides concentrations might be
useful in the clinical assessment of patients with IPF.
Jackson et al. [24] measured isoprostanes, total anti-
oxidant capacity (TAC) and H2O2 in plasma and urine
samples of 29 IPF patients and six healthy controls. IPF
patients also underwent a standardized bicycle exercise
protocol to quantify dyspnea. IPF plasma isoprostane
values did not change significantly after exercise, but
they clearly exceeded the normal control range for the
assay. By contrast, IPF urine isoprostane concentrations
increased significantly after exercise. Moreover, plasma
TAC decreased significantly after exercise, along with
the increment of lactate concentrations and hypoxemia,
indicating increased systemic oxidant stress. There were
no statistical differences in H2O2 urine concentrations
between IPF patients, both at baseline and after exercise,
and healthy subjects. The authors concluded that IPF
patients have evidence of systemic oxidant stress at rest,
and that low-level exercise produces reactive oxygen
species in this group.
Similarly, Malli et al. [25] observed higher serum con-
centrations of 8-isoprostane in 16 IPF patients when
compared to 17 healthy controls [median 77.25 pg/ml
(IQR 52.42–162.5 pg/ml) vs 18.88 pg/ml (IQR 15.90–
32.73 pg/ml)]. Muramatsu et al. [26] retrospectively
evaluated the effect of inhaled N-acetylcysteine (NAC)
monotherapy on redox balance and lung function, in 22
patients with early untreated IPF and 29 controls, in
one of the few studies published which evaluated OS
biomarkers in antioxidant therapies. FVC, blood con-
centrations of total glutathione (tGSH) and oxidized
glutathione (GSSG), as well as the tGSH/GSSG ratio,
and urine concentrations of 8-hydroxy-2′-deoxyguano-
sine (8OHdG) were measured at baseline, 6 and
12 months after initiating the treatment. The patients
were divided in two groups according to the response
to treatment at six months: patients with disease pro-
gression (FVC decrease of ≥5%), and patients with
stable disease (FVC decrease of < 5%). Baseline tGSH
concentrations and tGSH/GSSG ratio were both signifi-
cantly lower in IPF patients than in healthy controls, while
baseline GSSG concentrations in IPF patients were signifi-
cantly higher than those in controls. Mean temporal
changes in tGSH in patients with stable disease were simi-
lar to those in patients with progressive disease. However,
baseline and follow-up GSSG concentrations in patients
with stable disease were significantly higher than patients
with progressive disease. The baseline tGSH/GSSG ratio
was significantly lower in patients with stable disease
when compared to patients with progressive disease, and
the mean change during the follow-up was variable. More-
over, there was a significant negative correlation between
the change in GSSG and the change in FVC, and a signifi-
cant positive correlation between the change in tGSH/
GSSG ratio and the change in FVC.
Fig. 2 Flow chart showing the literature search and selection. Specific reasons for exclusion of studies are also shown
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Table 1 Summary of the oxidative stress biomarkers studied in different specimens of IPF patients
Biological specimens Comparison (n) Oxidative stress biomarkers Ref.
Plasma IPF (36) vs Ctrl (31) TEAC↓; PSH↔; MDA↑ 21
Plasma IPF/UIP (10) vs Ctrl (10) Hydroperoxides↑ 22
Plasma and urine IPF (29) vs Ctrl (6) Pl-isoprostanes↑; Ur-H2O2↔ 24





Serum IPF (16) vs Ctrl (17) 8-Isoprostane↑ 25
Blood IPF (22) vs Ctrl (29) GSH↓; GSSG↑; GSH/GSSG↓ 26
Serum IPF (43) vs Ctrl (30) Hydroperoxides↑ 27
Serum AE-IPF (13) vs IPF (30) Hydroperoxides↑ 27
Plasma IIP (31-9IPF) vs Ctrl (33) TOS↑; OSI↑; TAS↔ 28
Blood and plasma IPF (10) vs Ctrl (9) Bl-GSH↓;Bl-GSSG↔; Bl-Vitamin C↔
Pl-Uric acid↔; Pl-TEAC↓
29
Breath ILD (34-13IPF) vs Ctrl (9) Ethane ↑ 30
Sputum IPF (16) vs Ctrl (15) GSH↓ 31
EBC IPF (16) vs Ctrl (15) H2O2↑; 8-isoprostane↑ 33
EBC IPF (38) vs Ctrl (14) MDA↔ 34
EBC IPF (20) vs Ctrl (20) 3NT↑; NOx↔; Proteins↑;
8-isoprostane↑;H2O2↔;
35
EBC IPF (6) vs lung cancer (6) 8-isoPGF2α↑ 36
ELF IPF (44) vs Ctrl (11) MPO↑ 42
ELF IPF (15) vs Ctrl (19) tGSH↓; GSH/(GSH + GSSG) ↔ 46
ELF IPF (10) vs Ctrl (10) tGSH↓; rGSH↓ 49
ELF IPF (17) vs Ctrl (14) tGSH↓ 50
BALF IPF smokers (8) vs Ctrl smokers (6) Protein carbonyls↔ 52
BALF IPF nonsmokers (9) vs
Ctrl nonsmokers (14)
Protein carbonyls↑ 52
BALF IPF (9) vs Ctrl (5) Protein carbonyls↑ 54
BALF IPF (13) vs Ctrl (5) Protein carbonyls↑ 55
BALF IPF (15) vs Ctrl (8) Protein carbonyls↑ 56
BALF s-IPF (17) vs f-IPF (10) isocitrate dehydrogenase↓; peroxiredoxin 1↓; antithrombin III↓;
complement factor B↓
57
BALF IPF (17) vs Ctrl (14) tGSH↔ 50
BALF IPF (36) vs Ctrl (31) TEAC↓; GSH↓; GSSG↔; PSH↓; MDA↑ 21
BALF IPF (17) vs Ctrl (27) GSH↔; Uric Acid↑; Ascorbic Acid↑;
α-tocopherol↑; retinol↑; GSSG↑; F2-isoprostanes↔
58
BALF IPF (16) vs Sarcoidosis (55) 8-isoprostane↓ 25
Lung tissue IPF (10) vs Ctrl (10) ECSOD↔ 59
Lung tissue IPF fibrotic areas vs
IPF normal areas
ECSOD↓ 59
Lung tissue IPF (10) vs Ctrl (10) PrxII ↔ 60
Lung tissue IPF fibrotic areas vs
IPF normal areas
PrxII↓; 3-NT↓ 60
Lung tissue IPF (7) vs Ctrl (7) NRF2↔; SRX1↑ 61
Lung tissue IPF hyperplastic epithelium vs IPF normal epithelium NRF2↑; KEAP1↑ 61
Lung tissue IPF (14) vs Ctrl (10) GST ↓; Hp↓ 63
Lung tissue IPF (14) vs fNSIP (8) PRDX6↓; TPxB↓; 63
Lung tissue IPF (13) vs Ctrl (15) Cys↑; Gly↑; Glu↑ 64
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Finally, ROC curves analysis showed that GSSG base-
line concentrations ≥1.579 μmol/L yielded the best sen-
sitivity (69%) and specificity (100%) in discriminating
between stable and progressive disease. The authors
concluded that baseline GSSG concentrations may pre-
dict the efficacy of inhaled NAC for IPF, and that early
therapeutic intervention with a GSH precursor may
delay IPF progression, especially in patients with higher
pre-treatment whole blood GSSG concentrations.
Matsuzawa et al. [27] measured serum hydroperoxide
concentrations in 43 treatment-naïve IPF patients and
30 healthy controls, using d-ROMs. Among the 43 IPF
patients, 27 had been followed-up for six months; fur-
thermore, hydroperoxide concentrations were measured,
before treatment, in 13 cases with acute exacerbation.
Hydroperoxide concentrations in IPF patients were sig-
nificantly higher than those in controls [median 366 U.
CARR (IQR 339–443) vs. 289 U.CARR (IQR: 257–329),
respectively]. Oxidative stress values showed no signifi-
cant correlation with DLCO (%) or FVC (%) in patients.
Hydroperoxide concentrations significantly increased in
22 of the 27 patients followed-up for six months. There
was no significant difference in baseline oxidative stress
parameters between “rapid progressors” (n = 13) and
“slow progressors” (n = 14), but the magnitude of the in-
crease was greater in “rapid progressors” after 6 months.
Furthermore, serum hydroperoxide concentrations in
the 13 patients with acute exacerbation were signifi-
cantly higher than those of patients with stable disease
[median, 587 U.CARR (IQR: 523–667) vs. 366 U.CARR
(IQR: 339–443)]. The authors concluded that, since hy-
droperoxides in IPF were significantly correlated with
lower FVC and acute exacerbation, oxidative stress may
be involved not only in IPF development, but also in its
progression.
Ugurlu et al. [28] measured total oxidant status (TOS),
total antioxidant status (TAS), and oxidative stress index
(OSI) in 31 patients with idiopathic interstitial pneumo-
nia (IIP) including 9 patients with IPF, and 33 healthy
controls. IIP patients showed higher TOS and OSI
values, but similar TAS levels when compared to con-
trols. There was a negative association between TOS
and erythrocyte deformability measured at 1.69 Pa, as
well as a positive correlation between TAS and erythro-
cyte deformability measured at 5.33 Pa in IIP patients.
These findings suggest that the increased red blood cell
aggregation, mediated by oxidative stress, might further
disrupt tissue oxygenation in patients with IIP.
Veith et al. [29] measured, in 11 non-smoking patients
with IPF and 9 non-smoking healthy controls matched
for age, gender and dietary behaviour, blood GSH,
GSSG, TEAC, vitamin C and uric acid concentrations.
GSH concentrations were approximately 50% lower in
IPF patients when compared to controls (6.6 ± 0.6 vs 12.
9 ± 1.9 μmol/mg Hb), whereas GSSG concentrations did
not significantly differ between the two groups. The total
plasma antioxidant capacity in IPF patients was signifi-
cantly lower when compared to that of controls (483.1 ±
29.5 vs 619.7 ± 16.6 μmol/L Trolox equivalent). The
concentrations of uric acid and vitamin C, two endogen-
ous antioxidants known to contribute substantially to
the total plasma antioxidant status, were slightly, but not
significantly, lower in IPF patients than in controls.
Despite some discrepancy in the results and variability of
the methods employed, studies on blood markers reported
an increased OS in patients with IPF, which correlates with
clinical and functional parameters. Furthermore, OS bio-
markers were significantly altered in more severe and
rapidly progressive forms and, in some circumstances, pre-
dicted the efficacy of inhaled therapy with NAC. This sug-
gests their potential use in the assessment and monitoring
of these patients.
Biomarkers of OS in breath and sputum
The non-invasive measurement of biomarkers in breath
or sputum, albeit potentially attractive, is currently lim-
ited by issues regarding reproducibility and sensitivity.
Kanoh et al. [30] measured exhaled ethane (a product
of lipid peroxidation) in 34 patients with ILD, including
13 with IPF, and 16 control subjects on hospital admis-
sion and after three weeks. Exhaled ethane concentra-
tions were significantly higher in ILD patients when
compared to controls. Serial measurements revealed that
changes of ethane concentrations were associated with
disease progress by classifying ILD patients into an IPF
group and a non-IPF group. Using an estimated normal
range value for exhaled ethane, 4.9 pmol/dL, obtained by
adding 2 S.D. values to the mean value in healthy volun-
teers, the authors found that ethane concentrations were
significantly higher in IPF patients. In this group, four
patients showed a decrease to less than 5.0 pmol/dL after
three weeks of treatment with corticosteroids and im-
munosuppressive agents. These patients showed no subse-
quent exacerbations and remained stable. The remaining
patients died or experienced significant deterioration.
Beeh et al. [31] measured GSH concentrations in
induced sputum of 16 non-smoking IPF patients and 15
healthy subjects. The tGSH concentrations in IPF suf-
ferers was about four-fold lower than that of controls
(mean GSH 1.4 ± 0.34 μmol/L vs 5.8 ± 0.98 μmol/L).
There was an inverse association between GSH sputum
concentrations and disease severity, and a positive cor-
relation between GSH and vital capacity (VC, %), but
not DLCO (%).
These studies suggest that the measurement of exhaled
ethane or GSH in sputum might be useful in the clinical
evaluation and monitoring of patients with IPF. Never-
theless, the evaluation of OS in breath or sputum in
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these patients warrant further investigations because of
the relatively small sample size of published studies and
the different OS biomarkers measured with different
techniques.
Biomarkers of OS in exhaled breath condensate
Several mediators have been detected in EBC. However,
various factors, highlighted in the recent recommenda-
tions by the ERS, may affect their measurement [32]. An
important limitation of this approach is the low mea-
sured concentrations (often near to the detection limits),
which might significantly increase variability. Psathakis
et al. [33] measured EBC concentrations of H2O2 and 8-
isoprostane in 16 patients with IPF and 15 healthy sub-
jects. The mean concentration of H2O2 was significantly
higher in patients than in healthy subjects [0.36 μmol/L
(95% CI 0.24–0.47) vs. 0.16 μmol/L (95% CI 0.10–0.23)].
The authors observed non-detectable concentrations of
H2O2 in four controls. The mean concentration of 8-
isoprostane was also significantly higher in IPF patients
compared to controls [74 pg/mL (95% CI 38–110) vs.
33 pg mL (95% CI 28–39)]. There was no significant
correlation between H2O2 and 8-isoprostane concentra-
tions in IPF patients. A negative correlation between
H2O2 and DLCO was observed, however there were no
other significant correlations between both markers and
pulmonary function tests or pO2. Moreover, H2O2 and
8-isoprostane were not correlated with BALF cell count.
In summary, this study evidenced that EBC H2O2 and 8-
isoprostane concentrations are significantly higher in
patients with IPF when compared to healthy subjects,
and that the concentrations of H2O2 seem to be associ-
ated with disease progression.
Bartoli et al. [34] did not observe significant between-
group differences in EBC MDA concentrations in 38 IPF
patients and 14 healthy subjects. The authors hypothe-
sized that treatment with oral corticosteroid and/or N-
acetyl-cysteine in most IPF patients might have lowered
per se EBC MDA concentrations.
Chow et al. [35] collected EBC in 20 IPF patients and
20 controls and measured several oxidative stress and
inflammatory biomarkers, including total nitrogen ox-
ides (NOx), 3-nitrosotyrosine (3-NT), 8-isoprostane,
total proteins, H2O2 as exhaled nitric oxide (FeNO) and
carbon monoxide (eCO). EBC 3-nitrotyrosine was higher
in IPF patients compared to controls [2.5 ng/mL (range
0.7–8.9) vs 0.3 ng/mL (0.1–1.1). 3-NT concentrations
significantly correlated with other biomarkers, such as
total NOx, 8-isoprostane, total proteins, and H2O2.
Moreover, there was a significant inverse relationship
between EBC 3-NT concentrations and FEV1 (%), FVC
(%), VC (%), and total lung capacity (TLC, %). No sig-
nificant between-group differences in total NOx were
observed. Furthermore, NOx did not correlate with
parameters of lung function. The authors found that
IPF patients had significantly higher EBC total protein
concentrations than control subjects. Total proteins
significantly correlated with 8-isoprostane, H2O2 and
3-NT, but not with lung function. Mean EBC 8-
isoprostane concentrations were also higher in IPF pa-
tients when compared to normal subjects [0.2 ng/mL
(range 0.1–0.4) vs 0.08 ng/mL (0.04–0.2). Correlation
analysis showed significant associations between 8-
isoprostane and total proteins, H2O2, NOx and 3-NT,
but not with lung function. There were no between-
group differences in EBC H2O2 concentrations. H2O2
concentrations were significantly associated with NOx,
3-NT, 8-isoprostane and total protein, but not with
lung function.
Finally, Shimizu et al. [36] measured EBC concentra-
tions of the oxidative stress marker 8-iso prostaglandln-
F2α (8-isoPGF2α) in IPF patients and control subjects.
Isoprostanes are prostaglandin (PG)-like substances that
are generated through peroxidation of unsaturated fatty
acids by free radicals [37]. The isoprostane 8-isoPGF2α is
an isomer of PGF1 that is generated by peroxidation of
arachidonic acid. 8-isoPGF2α concentrations were signifi-
cantly higher in IPF patients than control subjects (24.5 ±
15.8 pg/ml vs 4.6 ± 1.0 pg/ml, p < 0.05), and suggested that
oxidative stress may promote the progression of IPF via
ROCK (Rho-associated coiled-coil containing protein kin-
ase) activation. The ROCK pathway is involved in myofi-
broblast contractility via relaxin (an insulin family
peptide) in lungs with IPF and in mice with bleomycin-
induced lung fibrosis [38]. ROCK activation may induce
contraction of airway and arterial smooth muscle cells,
and is involved in angiogenesis impairment [39, 40];
both events have been reported to be involved in the
pathogenesis of IPF [41, 42].
Biomarkers of OS in epithelial lining fluid
One of the first evidence of oxidative stress in IPF was
described by Cantin et al. [43] in 1987, who showed that
patients with IPF had markedly increased ELF concen-
trations of myeloperoxidase (MPO). MPO, a member of
the XPO subfamily of peroxidases, produces hypochlor-
ous acid (HOCl) from hydrogen peroxide (H2O2) and
chloride anion (Cl−) or the equivalent from a non-
chlorine halide during the neutrophil’s respiratory burst.
Furthermore, it oxidizes tyrosine to tyrosyl radical using
hydrogen peroxide. The cytotoxic action of hypochlor-
ous acid and tyrosyl radical impairs antimicrobial cap-
acity of neutrophils [44, 45]. The authors found that the
incubation of IPF ELF with cultured alveolar epithelial
cells in the presence of H2O2 caused increased cellular
injury, which was suppressed by methionine, a myelo-
peroxidase system scavenger. The ability of IPF ELF to
augment H2O2-mediated injury to lung parenchymal
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cells in vitro, additionally, correlated with the ELF concen-
tration of MPO. Moreover, the VC deterioration rate was
greater in patients with increased ELF MPO than in those
without. These findings suggest that IPF ELF potentially
increases epithelial cell cytotoxicity by highly reactive
hypohalous anion formation. This toxic radical can oxidize
various biomolecules, inducing alterations in critical cellu-
lar components and cell death, contributing, at least in
part, to the severe epithelial cell injury typical of IPF.
The same authors reported subsequently [46] that the
ELF concentration of total glutathione [reduced (GSH)
+ oxidized (GSSG)] in IPF was significantly lower than
that of healthy subjects (97 ± 18 μmol/ vs 429 ±
34 μmol/L). However, ELF glutathione did not correlate
with respiratory function tests. Despite differences in the
total content of GSH, the ratio of (GSH)/(GSH +GSSG)
in patients with IPF was similar to that observed in
normal subjects (94 ± 4% vs 98 ± 2%), suggesting that the
reduction of GSH in IPF is primarily caused by direct
GSH oxidation in the ELF milieu. Starting from the
assumption that ELF GSH is derived from epithelial
cells, the authors hypothesized that the chronic oxidant
burden in IPF causes an alteration in their ability to
synthesize, store and secrete GSH. In this regard, studies
in neutrophils and lung tissue have shown that OS
reduces the intracellular concentrations of both GSH
and GSSG [47, 48], and that oxidative stress in general
may affect GSH transport in epithelial cells.
The findings of Cantin et al. in ELF GSH were con-
firmed by two further studies. Borok et al. [49] in 1991
reported lower ELF concentrations of total and reduced
GSH in IPF patients when compared to controls. As for
the work of Cantin et al. [46] reduced GSH was more
than 90% of total ELF glutathione both in IPF sufferers
and in controls. IPF subjects were treated with GSH,
600 mg twice daily for 3 days, by aerosol. One hour after
the first aerosol the ELF tGSH concentrations were sig-
nificantly increased. After repeated dosing for 3 days,
the average concentration of tGSH was slightly, but not
significantly, higher than the pre-therapy concentration,
while ELF GSSH increased significantly. A decrease in
the spontaneous release of superoxide anion (O2
−) by
alveolar macrophages was observed in all subjects.
Concentrations of tGSH in ELF were also measured by
Meyer et al. [50], before and after oral therapy with 3 ×
600 mg NAC per day for 5 days, in 17 non-smoking pa-
tients with IPF. Pre-treatment total glutathione levels in
ELF were 187 ± 36 μmol/L, significantly lower than that
in normal subjects (368 ± 60 μmol/L). After therapy with
NAC, ELF tGSH concentrations increased to 319 ±
92 μmol/L, close to normal values, even if this increase
was not statistically significant.
These studies, other than their contribution on the un-
derstanding of some of the pathophysiological mechanisms
leading to oxidative imbalance in IPF through GSH oxida-
tion, showed that the measurement of GSH in ELF may be
useful for the monitoring of OS reduction to specific treat-
ments. Nevertheless, the clinical utility of these responses
should be further investigated, because the ELF GSH con-
centrations were shown not to correlate with respiratory
function tests in IPF patients.
Biomarkers of OS in bronchoalveolar lavage fluid
BALF is a diagnostic procedure assessing cellular and
non-cellular components of the epithelial lining fluid of
the alveolar and bronchial airspaces for diagnostic,
therapeutic, and research purposes. Though BALF is an
invasive approach, it is usually well-tolerated and safe in
IPF patients [51]. The quantification of biomarkers in
the supernatant may be challenging, due to the lack of a
satisfactory marker for the dilution of the saline lavage.
This is one of the factors that may contribute to the
variability in measurements, particularly in studies of
limited sample size.
BALF from patients with IPF were analysed by Lenz
et al. [52] to evaluate oxidized proteins. The oxidation of
proteins, usually accompanied by the introduction of
carbonyl groups into their amino acid side-chains, can
be measured by labelling these groups with several vali-
dated methods [53]. The authors found that carbonyl
proteins concentrations were higher in IPF non-smokers
when compared to healthy non-smokers (8.3 ± 0.7 vs 5.3
± 0.6 nmol/mg protein), whereas the IPF smoking group
showed decreased levels of carbonyl proteins vs. healthy
control smokers (5.9 ± 0.9 vs 8.3 ± 1.5 nmol/mg protein).
The total BALF carbonyl protein concentrations in the
whole IPF cohort correlated significantly with absolute
eosinophil, polymorphonuclear, and neutrophil counts.
The same authors [54] confirmed later that the oxida-
tive status of BALF proteins, defined as carbonyl protein
groups, is 2.4-fold higher in IPF. They also described an
inverse relationship between the carbonyl content of
BALF proteins and glutathione peroxidase mRNA levels,
and a positive correlation between oxidized proteins and
TNF-α, IL-1b and IL-8 in IPF patients. The authors hy-
pothesized the involvement of an IL-8 dependent mech-
anism in the marked shift in favour of oxidants in IPF.
Similarly, Rottoli et al. [55] found that IPF patients had
significantly higher concentrations of oxidised BALF pro-
teins than controls through a proteomic approach, which
revealed that protein carbonylation involved specific
carbonylation-sensitive proteins, and that in IPF a greater
number of proteic targets of oxidation were present, in-
cluding albumin, transferrin, α1-antitrypsin, complement
C3, SOD, ceruloplasmin, pulmonary surfactant-associated
protein A, and many others. The authors confirmed these
findings [56] reporting that the protein carbonyl content
in IPF BALF of 15 patients were four-fold higher than in
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controls. In the latter study however, no correlations were
found between carbonylated protein concentrations and
BALF cell populations, either in the IPF or in the control
group.
Again, by means of proteomic differential analysis,
Carleo et al. [57] investigated the protein patterns of
BALF samples in 10 familial (f-) IPF and 17 sporadic (s-)
IPF patients. s-IPF patients showed up-regulation of
proteins involved in oxidative stress response, including
isocitrate dehydrogenase, peroxiredoxin 1, antithrombin
III, and complement factor B. The identified proteins
were functionally involved in several biological processes
such as ‘cellular iron ion homeostasis’, ‘response to stimulus’,
‘response to stress’, ‘acute inflammatory response’, and
others. The authors underlined that differentially expressed
proteins in their study are common biomarkers in con-
nective tissue diseases and autoimmune diseases, and this
may imply pathophysiological similarities between these
conditions and IPF.
Meyer et al. [50] measured BALF GSH concentrations,
before and after oral therapy with 3 × 600 mg NAC per
day for 5 days, in 17 non-smoking patients with IPF.
Pre-treatment tGSH in BALF (0.99 ± 0.12 μmol/L) was
similar to controls (1.18 ± 0.19 μmol/L; p > 0.5). After
therapy with a total of 15 doses of 600 mg NAC, BALF
GSH levels significantly increased to 1.54 ± 0.24 μmol/L,
within the normal range. The authors emphasised that
GSH levels remained high at 10 ± 0.5 h after the last
treatment dose.
Rahaman et al. [21] measured several parameters of
oxidant/antioxidant balance in BALF of 24 patients with
IPF (17 non-smokers and 7 smokers), and 31 healthy
subjects (23 non-smokers and 8 smokers). Antioxidant
capacity, measured as TEAC, was significantly higher in
healthy smokers, compared with healthy non-smokers,
while all IPF patients (both smokers and non-smokers)
showed lower levels of TEAC when compared to healthy
subjects. BALF protein thiols were significantly de-
creased in non-smoking IPF patients and were similar in
IPF smokers compared to either healthy non-smokers or
smokers. The authors also found a significant increase in
BALF proteins in both groups of patients with IPF com-
pared to healthy individuals. Analysis of GSH levels in
BALF in this study revealed that GSH concentrations
were significantly lower in IPF non-smokers compared
with healthy non-smokers. In contrast, GSH levels were
significantly higher in IPF smokers when compared to
non-smokers, while no differences were observed with
healthy smokers. Evaluation on GSSG levels showed no
significant differences in any of the IPF groups when
compared to healthy subjects. However, the GSH/GSSG
ratio was higher, 73% and 208%, in healthy smokers and
smoking IPF patients, respectively, when compared with
healthy non-smokers. By contrast, the GSH/GSSG ratio
was significantly lower, 64%, in IPF non-smokers com-
pared to healthy non-smokers. In addition, the authors
analysed the products of lipid peroxidation in BALF and
found that the levels of lipid peroxides were higher in
the global IPF cohort when compared to healthy sub-
jects; in particular, MDA levels were significantly higher
in patients with IPF who were smokers when compared
to healthy smokers.
Markart et al. [58] measured several non-enzymatic
low-molecular-weight antioxidants such as GSH, uric
acid, ascorbic acid (vitamin C), retinol (vitamin A), and
tocopherol (vitamin E) in BALF from 16 patients with
IPF. Additionally, they determined BALF plasmalogen
levels, the alk-1-enyl-acyl subclass of phosphatidyletha-
nolamine and phosphatidylcholine, a potent antioxidant.
The most abundant antioxidant molecule in BAL fluids
in the control group was GSH, followed by uric acid and
ascorbic acid. The levels of GSH were not significantly
altered in IPF patients. By contrast, uric acid levels were
significantly higher in IPF patients compared to controls.
Similarly, a significant increase in ascorbic acid concentra-
tions was observed in IPF patients (0.87 ± 0.14 μmol/L) vs.
controls (0.48 ± 0.04 μmol/L). Moreover, IPF BALF con-
centrations of both lipophilic antioxidants were strongly
increased compared with controls. A significant increase
of GSSG, and a trend toward raised levels of F2-
isoprostanes, were also reported in IPF BALF. By contrast,
plasmalogen concentrations did not significantly differ be-
tween cases and controls, and no significant relationships
were observed between the concentrations of the studied
antioxidants, pulmonary function, and parameters of gas
exchange.
Malli et al. [25], other than their studies on blood pre-
viously described, compared the levels of 8-isoprostane
in BALF of 16 IPF subjects and 55 sarcoidosis patients.
Individuals with sarcoidosis had significantly higher 8-
isoprostane BALF concentrations when compared to IPF
patients [median 220.6 pg/mL (IQR: 133.6–403.3) vs 74.
87 pg/mL (IQR. 62.23–115.1), respectively].
The quantification of biomarkers in BALF may be chal-
lenging, due to the lack of a satisfactory marker for the
dilution of the saline lavage. This is one of the factors that
may contribute to the variability in the measurements
described, particularly in studies with small sample size.
Nevertheless, some studies showing encouraging detection
capacity, and previous adequate standardization, might
provide alternative options in OS evaluation and moni-
toring in IPF.
Biomarkers of OS in lung tissue
Kinnula et al. [59] reported similar extracellular immu-
noreactivity of superoxide dismutase (ECSOD), the
major antioxidant enzyme of the human lung extracellu-
lar matrix, in vascular endothelium, bronchial epithelium
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and alveolar macrophages of 10 patients with biopsy-
proven IPF and controls. UIP regenerative alveolar epithe-
lium showed variable ECSOD positivity. Fibrotic lesions
and fibroblastic foci were negative for ECSOD. To
confirm this finding, the authors excised fibrotic and non-
fibrotic areas from OCT-embedded non-fixed frozen sec-
tions of UIP lungs to compare ECSOD by western blotting
analysis. The findings, in agreement with the immunohis-
tochemical results, confirmed that ECSOD immunoreac-
tivity was significantly lower in fibrotic vs. non-fibrotic
areas. The granular cells of the interstitium were the only
cells demonstrating intense ECSOD staining in fibrotic
areas. The authors hypothesized that the decreased levels
of ECSOD in fibrotic areas of UIP may further increase
the oxidant burden of the disease.
Vuorinen et al. [60] studied peroxiredoxin (Prx) II, an
antioxidant that has been associated with platelet-
derived growth factor (PDGF) signalling, and consequent
cell proliferation. Localization and expression of Prx II,
PDGF receptors (PDGFRa, PDGFRb), Ki67 (a marker of
cell proliferation), and nitrotyrosine (a marker of
oxidative-nitrosative stress) were assessed in ten IPF/UIP
lung biopsies and ten controls by immunohistochemistry
and morphometry. The results suggest that Prx II oxida-
tion does not play a significant role in the pathogenesis
of IPF/UIP and that Prx II, PDGFRs, and proliferating
cells co-localize in the IPF/UIP lung and FF.
Mazur et al. [61] analysed the Nrf2 –sulfiredoxin-1
(SRX1) pathway by several methods to assess the cell-
specific localization and expression of NRF2 and SRX1,
and selected proteins linked to their activation or stabil-
ity in human IPF and non-specific interstitial pneumonia
(NSIP) patients. Nrf2 induces several antioxidant en-
zymes [62], including the rate-limiting enzyme in GSH
synthesis, gammaglutamyl cysteine ligase, as well as
glutathione-S-transferases, thioredoxins, peroxiredoxins,
and hemeoxygenase-1. Increased oxidative stress favours
the dissociation of the cytoplasmic Kelch-like ECH-
associated protein-1 (KEAP1)- NRF2 complex. Conse-
quently, released Nrf2 translocates to the nucleus where
it binds to the antioxidant responsive element, and initi-
ates the transcription of the above-mentioned enzymes
involved in protection from oxidative stress. Oxidants
can also provoke protein and thiol oxidation, nitrosyla-
tion and carbonylation. The SRX1 enzyme, regulated by
Nrf2, catalyses the reduction of these altered moieties
back to their active forms. Non-specific cell variability in
the expression of the Nrf2 pathway was observed both
in healthy and diseased lungs. By contrast, SRX1 was in-
creased in IPF compared to controls. Immunohisto-
chemistry revealed that proteins of the Nrf2 pathway
were localized in the hyperplastic alveolar epithelium
and inflammatory cells of IPF lung tissue, but were ab-
sent in the fibroblastic foci, which is a characteristic trait
of IPF. Morphometric evaluation revealed that Nrf2 and
KEAP1 were significantly increased in the hyperplastic
alveolar epithelium compared to the normal alveolar
epithelium, and Nrf2 was markedly expressed in the nu-
clear compartment of the hyperplastic cells. SRX1 was
expressed mainly in alveolar macrophages, and the num-
ber of SRX1-positive macrophages/surface area was ele-
vated in NSIP, a disease with greater inflammatory
activity compared to IPF. The authors concluded that
the expression of the Nrf2 pathway in human IPF, and
NSIP, represents further evidence that the pathogenesis
of human fibrotic lung diseases is oxidant-mediated and
originates from the alveolar epithelium.
Korfei et al. [63] performed comparative proteomic
analysis of peripheral lung tissue from 14 with IPF
patients, 8 fibrotic non-specific interstitial pneumonia
(fNSIP) and 10 organ donors, by using the 2-dimensional
DIGE technique and MALDI-TOF-MS. Downregulated
proteins in IPF and fNSIP included antiapoptotic factors
and antifibrotic molecules, as well as antioxidant enzymes
such as glutathione transferase and haptoglobin. Upregu-
lated proteins included stress-induced molecules involved
in the ER stress-pathway, such as leucine aminopeptidase
(LAP3) and peptidylprolyl isomerase A (PPIA). The
authors found that the IPF and fNSIP proteomic pattern
differed only for the expression of a few proteins like the
antioxidant acting proteins peroxiredoxin 6 (PRDX6) and
thioredoxin peroxidase B (TPxB). The authors advocate
that key molecular events in the pathogenesis of IPF and
fNSIP are localized in the alveolar epithelium and suggest
that antioxidant therapeutic approaches may inhibit detri-
mental oxidant-mediated reactions, which seem originat-
ing mainly from chronic stress.
Finally, a metabolomics approach was used by Kang
et al. [64] to characterize metabolic changes of lung tissues
involved in the pathogenesis of IPF using gas chromatog-
raphy−mass spectrometry based metabolic profiling. Ana-
lyses were performed on lung tissue samples of 13
patients with IPF and 15 controls. Partial least-squares
discriminant analysis (PLS-DA) model generated from
metabolite data discriminated between control subjects
and IPF patients (receiver operator characteristic area
under the curve, AUC > 0.9). In univariate and multivari-
ate statistical analyses twenty-five metabolite signatures of
IPF were detected, primarily involving GSH synthesis,
including cysteine, glycine, and glutamic acid, found at
higher concentration in IPF.
The contribution of studies on IPF tissues was essential
for the understanding of several pathogenic mechanisms
involving numerous OS protein networks and molecular
interplays. The main advantage of lung biopsies is that
they directly sample the parenchyma, maintaining the
spatial relationships of structural components thus allow-
ing to clearly identify tissue districts in which oxidative
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stress is present. However, its invasiveness limits patient’s
acceptance and justifies its use primarily in situations
where the diagnosis remains uncertain with less invasive
approaches [48].
Antioxidants for the treatment of IPF
Considering that oxidative stress is widely recognized as
a central feature of IPF, antioxidant therapy has been
proposed for many years. In particular, N-acetylcysteine
has been widely used in IPF as antioxidant and antifibro-
tic agent since it is relatively inexpensive, well-tolerated,
and easy to administer orally. However, scientific data
were often conflictual or inconclusive, mainly due to the
lack of placebo arm and the low statistical power.
Two recent papers reported meta-analyses of trials in-
vestigating the efficacy of antioxidant therapy in IPF. Sun
et al. [65] included 5 trials, with a total of 564 patients, to
evaluate the efficacy of NAC in the treatment of IPF. N-
Acetylcysteine was found to have a significant beneficial
effect on predicted VC and 6 min walking test distance
(6 min-WTD), but not on FVC, DLCO, rates of adverse
events and mortality. In another meta-analysis, Kandhare
et al. [66] identified twelve studies (n = 1062) investigating
the antioxidants NAC and lecithinized SOD, alone or in
combination with other drugs such as pirfenidone, azathi-
oprine, prednisone, to treat IPF. There was no evidence
that antioxidant monotherapy had any beneficial effects
on changes in predicted DLCO. Combined antioxidant
therapy was more effective than monotherapy on VC and
DLCO, however this did not translate into differences in
death rates or adverse events.
These meta-analyses included the most relevant clin-
ical trials, such as the IFIGENIA and PANORAMA
studies [67, 68], which used different methods, control
groups, and clinical or functional criteria (rather than
biomarkers of OS) in evaluating NAC in IPF. Their find-
ings are in contrast with the results of the PANORAMA
study [68], which showed that the NAC plus pirfenidone
group had an increased incidence of photosensitivity
compared to pirfenidone alone, and a more rapid disease
progression, measured as FVC change. This has been
discussed by Wijsenbeek and Collard [69] in their com-
ment on the PANORAMA study results, underlying that
acetylcysteine therapy cannot be currently recommended
to patients with IPF.
Although the 2015 updated treatment guidelines for IPF
recommended against NAC [70] NAC monotherapy has
been shown to be associated with improved walk distance
and mental wellbeing in patients with IPF in other reports
[71]. In addition, recent evidence indicates that the re-
sponse to NAC therapy may be different on the basis of
TOLLIP genotype [72]. The gene TOLLIP play important
roles in the lung host defence, an immune process influ-
enced by oxidative signalling. In particular, it has been
found that NAC may be an effective therapy for individ-
uals with IPF with TOLLIP TT genotype but was associ-
ated with a trend toward harm in those with CC genotype.
Overall, the therapeutic potential of NAC for patients with
IPF remains undefined, and future pharmacogenomic
trials must be done to confirm the findings of this study.
Conclusions
It is currently accepted that IPF pathogenesis depends
on repetitive chronic cell injury, which triggers fibrosis
and oxidative imbalance within the lung. Causes of
oxidative stress include, but are not limited to, cell injury
itself, transition metal exposure, inflammation, or drugs
that participate in reduction–oxidation reactions. The
importance of oxidative modifications to the extracellu-
lar matrix, and how they alter cellular responses in
human IPF, remains to be elucidated. Since 1987, when
the first evidence of an imbalanced oxidant/antioxidant
system was described in IPF ELF, several researchers
have investigated oxidative stress biomarkers in this
pathology. This review summarizes their work on oxida-
tive stress indicators in IPF using different biological
sample sources (lung tissue, BALF, EBC, breath, sputum
or blood). Although interventional trials failed to dem-
onstrate significant effects of antioxidant treatments
(particularly NAC) recent evidence suggest the potential
role of pharmacogenomics in predicting efficacy.
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